November 27, 2017 | Two Israeli startups working on solutions to combat heart failure were among the three finalists at the Cardiovascular Research Foundation’s Shark Tank Innovation competition held at the 2017 TCT Conference in Denver, Colorado this month, according to a report in Israel21c. Shark Tank judges chose Israeli company Enospace Biomedical as the winner of this competition. The Caesarea-based heart failure treatment company is developing a minimally invasive implantable neurostimulation device called Harmony, which increases cardiac efficiency by reducing the work of the left ventricle. The company was founded in 2008 by Rainbow Medical Group. Third place went to Nazareth startup Paragate Medical, which is part of the NGT3 incubator there. Paragate is in the process of developing an implantable device programmed to remove the excess fluids produced in patients with heart failure or kidney disease. Startups that participated in this competition were judged on uniqueness, intellectual property, a professional staff, the ability to bring their product to market and the potential to make a change. Though 100s of companies applied, only 50 were chosen to continue on in the competition.